Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Item
http://www.wikidata.org/entity/Q37451255
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.Current Landscape of Targeted Therapy in Lung Cancer.Understanding and targeting resistance mechanisms in NSCLC.Targeting the Raf kinases in human cancer: the Raf dimer dilemma.Development of encorafenib for BRAF-mutated advanced melanoma.Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing.MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.Exome-wide somatic mutation characterization of small bowel adenocarcinoma.Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation.Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience
P2860

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Item
http://www.wikidata.org/entity/Q37451255
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Preclinical efficacy of a RAF ...... inase BRAF-mutant lung cancer.
@en
Preclinical efficacy of a RAF ...... inase BRAF-mutant lung cancer.
@nl
type
label
Preclinical efficacy of a RAF ...... inase BRAF-mutant lung cancer.
@en
Preclinical efficacy of a RAF ...... inase BRAF-mutant lung cancer.
@nl
prefLabel
Preclinical efficacy of a RAF ...... inase BRAF-mutant lung cancer.
@en
Preclinical efficacy of a RAF ...... inase BRAF-mutant lung cancer.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Preclinical efficacy of a RAF ...... inase BRAF-mutant lung cancer.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932